You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 10,376,601

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,376,601

Title:	In-vivo intravascular blood replacing liquid, in-vivo intravascular blood replacing liquid formulation, and prefilled syringe
Abstract:	An in-vivo intravascular blood replacing liquid of the present invention is injected into a blood vessel to replace blood at an intravascular portion to be inspected therewith in making an in-vivo intravascular inspection. The blood replacing liquid comprises an aqueous medium unharmful for a living body and a gelling property imparting substance, unharmful for the living body, which is added to the aqueous medium to impart a gelling property to the blood replacing liquid. The blood replacing liquid has a viscosity of not more than 3 mPas when the blood replacing liquid is injected into the blood vessel.
Inventor(s):	Nakamura; Koji (Hadano, JP), Mori; Isao (Chofu, JP), Tokida; Masanori (Fujinomiya, JP)
Assignee:	TERUMO KABUSHIKI KAISHA (Shibuya-Ku, Tokyo, JP)
Application Number:	15/277,405
Patent Claims:	1. An in-vivo intravascular blood replacing liquid comprising: an aqueous medium unharmful for a living body; a gelling property imparting substance, unharmful for said living body, which is added to said aqueous medium to impart a gelling property to said blood replacing liquid in an in-vivo intravascular inspection; said blood replacing liquid having a viscosity of not more than 3 mPas when said blood replacing liquid is injected into said blood vessel; and said gelling property imparting substance being mixtures of glycyrrhizin acids and thiamine chloride hydrochloride. 2. The in-vivo intravascular blood replacing liquid according to claim 1, wherein said aqueous medium is sterile water, saline, or a buffer solution. 3. The in-vivo intravascular blood replacing liquid, according to claim 1, wherein said blood replacing liquid has a viscosity of not more than 3 mPas at not more than 30 degrees C. and displays a gelling property at not less than 25 degrees C. 4. The in-vivo intravascular blood replacing liquid, according to claim 1, which contains a hydrophilic polymer as a viscosity modifier of the in-vivo intravascular blood replacing liquid. 5. The in-vivo intravascular blood replacing liquid according to claim 4, wherein said viscosity modifier is at least one selected from the group consisting of gelatin, methylcellulose, polyethylene glycol, polyvinylpyrrolidone, ficoll, polyvinyl alcohol, styrene-maleic anhydride alternating copolymers, divinyl ether-maleic anhydride alternating copolymers, polyvinyl methyl ether, polyvinyl methyl oxazoline, poly ethyl oxazoline, poly hydroxypropyl oxazoline, poly hydroxypropyl methacrylamide, polymethacrylamide, polydimethylacrylamide, poly hydroxypropyl methacrylate, polyhydroxyethyl acrylate, hydroxymethyl cellulose, hydroxyethyl cellulose, polyaspartamide, and synthetic polyamino acid. 6. An in-vivo intravascular blood replacing liquid formulation comprising a medical container and an in-vivo intravascular blood replacing liquid is contained therein, wherein said blood replacing liquid comprises an aqueous medium unharmful for a living body and a gelling property imparting substance comprising glycyrrhizin acids and thiamine chloride hydrochloride, unharmful for said living body, which is added to said aqueous medium to impart a gelling property to said blood replacing liquid; and said blood replacing liquid has a viscosity of not more than 3 mPas when said blood replacing liquid is injected into said blood vessel. 7. A prefilled syringe comprising an outer cylinder, a gasket accommodated inside said outer cylinder, a sealing part for sealing a front end portion of said outer cylinder, and an in-vivo intravascular blood replacing liquid is filled inside said outer cylinder, wherein blood replacing liquid comprises an aqueous medium unharmful for a living body and a gelling property imparting substance comprising glycyrrhizin acids and thiamine chloride hydrochloride, unharmful for said living body, which is added to said aqueous medium to impart a gelling property to said blood replacing liquid; and said blood replacing liquid has a viscosity of not more than 3 mPas when said blood replacing liquid is injected into said blood vessel. 8. A prefilled syringe, according to claim 7, which is subjected to heat sterilization with said intravascular blood replacing liquid being filled therein. 9. An in-vivo intravascular blood replacing liquid comprising: an aqueous medium unharmful for a living body; a gelling property imparting substance, unharmful for said living body, which is added to said aqueous medium to impart a gelling property to said blood replacing liquid in an in-vivo intravascular inspection; said blood replacing liquid having a viscosity of not more than 3 mPas when said blood replacing liquid is injected into said blood vessel; and said gelling property imparting substance being mixtures consisting of glycyrrhizin acids and thiamine chloride hydrochloride. 10. The in-vivo intravascular blood replacing liquid according to claim 9, wherein said aqueous medium is sterile water, saline, or a buffer solution. 11. The in-vivo intravascular blood replacing liquid, according to claim 9, wherein said blood replacing liquid has a viscosity of not more than 3 mPas at not more than 30 degrees C. and displays a gelling property at not less than 25 degrees C. 12. The in-vivo intravascular blood replacing liquid, according to claim 9, which contains a hydrophilic polymer as a viscosity modifier of the in-vivo intravascular blood replacing liquid. 13. The in-vivo intravascular blood replacing liquid according to claim 12, wherein said viscosity modifier is at least one selected from the group consisting of gelatin, methylcellulose, polyethylene glycol, polyvinylpyrrolidone, ficoll, polyvinyl alcohol, styrene-maleic anhydride alternating copolymers, divinyl ether-maleic anhydride alternating copolymers, polyvinyl methyl ether, polyvinyl methyl oxazoline, poly ethyl oxazoline, poly hydroxypropyl oxazoline, poly hydroxypropyl methacrylamide, polymethacrylamide, polydimethylacrylamide, poly hydroxypropyl methacrylate, polyhydroxyethyl acrylate, hydroxymethyl cellulose, hydroxyethyl cellulose, polyaspartamide, and synthetic polyamino acid.

Details for Patent 10,376,601

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006	⤷ Try a Trial	2034-03-28
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.